Activated Protein C Resistance: Molecular Mechanisms

• References

• 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 2 Dahlbäck B. Inherited thrombophilia: Resistance of activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614
• 3 Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
• 4 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
• 5 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 6 Halbmayer W-M, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinol 1994; 5: 51-57
• 7 Cadroy Y, Sie P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-2009
• 8 Bertina RM, Koeleman BP C, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 9 Greengard JS, Sun X, Xu X, Fernández JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362
• 10 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg⁵⁰⁶ of factor V. Lancet 1994; 343: 1535-1536
• 11 Greengard JS, Eichinger S, Griffin JH, Bauer KA. Brief report: Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg -> Gin mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-1562
• 12 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
• 13 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
• 14 Dahlbäck B, Carlsson M. Factor VIII defect associated with familial thrombophilia. Thromb Haemost 1991; 654: 658-658
• 15 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
• 16 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1499
• 17 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
• 18 Heeb MJ, Kojima Y, Greengard J, and Griffin JH. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln⁵⁰⁶-factor V. Ms.submitted. 1995
• 19 Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V to detect activated protein C resistant factor Fa in patient receiving warfarin and in patients with a lupus anticoagulant. Blood. in press 1995
• 20 Griffin JH, Calkins T, and Bylund D. An activated partial thromboplastin time assay for activated protein C resistance and Gln506-factor V in venous thrombosis patients taking Coumadin. Ms.submitted. 1995
• 21 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Vllla. J Biol Chem 1994; 269: 18735-18738
• 22 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombin ase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877
• 23 Koeleman BP C, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 24 Gandrille S, Greengard JS, Alhenc-Gelas M. et al. Incidence of activated protein C resistance due to the ARG 405 GLN mutation in factor V in 113 unrelated symptomatic protein C deficient patients. Blood. in press 1995
• 25 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation ofhuman factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880
• 26 Kane WH, Davie EW. Blood coagulation factors V and VIII: Structure and functional similarities and their relationship to hemonhagic and thrombotic disorders. Blood 1988; 71: 539-555
• 27 Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Functional studies of factor Va (FVa) residues 493-506 related to activated protein C (APC) resistance. Blood 1994; 84: 391a
• 28 Triplett DA. Antiphospholipid antibodies and thrombosis. Arch Pathol Lab Med 1993; 117: 78
• 29 Santoro SA. Antiphospholipid antibodies and thrombotic predisposition: Underlying pathogenetic mechanisms. Blood 1994; 83: 2389
• 30 Roubey AS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854
• 31 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426
• 32 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-107
• 33 Costing JD, Derksen RH W M, Bobbink IW G, Hackeng TM, Bouma BM, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism. Blood 1993; 81: 2618-2625
• 34 Smirnov M, Esmon C. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819
• 35 Amer L, Kisiel W, Searles RP, Williams Jr RC. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 1990; 57: 247-258